The Accelerating Clinical Trials in the EU (ACT EU) initiative has launched a call for nominations to renew the composition of its Multi-stakeholder Platform Advisory Group (MSP AG) for the 2027-2029 mandate.
The MSP AG supports dialogue between regulators and stakeholders on matters related to clinical trials and contributes to the continuous improvement of the EU clinical trials environment.
Organisations representing European patients and consumers, healthcare professionals, academia, industry and research funders are invited to submit nominations for one representative and one alternate.
In addition, based on the topics to be discussed during each MSP AG meeting, experts from other stakeholder groups may join on an ad hoc basis.
For the new mandate, we would welcome broader representation and reinforced expertise from principal investigators, health innovation and biotech start-up ecosystems, scale-up support organisations, investors, and public and private funders involved in supporting clinical research programmes.
The deadline for submissions is 30 October 2026 at 23:59 CET.
Further information on the role and current composition of the MSP AG is available on the Multi-stakeholder Platform webpage.
- 27 August 2026
Excerpt from the official page. The original is authoritative.